Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

Description: Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016

Summary

‘Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016’, provides in depth analysis on Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105).
- The report reviews Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- The report reviews key players involved in Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics and enlists all their major and minor projects.
- The report assesses Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The report summarizes all the dormant and discontinued pipeline projects.
- The report reviews latest news and deals related to Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics.

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D
strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents:
List of Tables
List of Figures
Introduction
Report Coverage
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) Overview
Therapeutics Development
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Stage of Development
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Therapy Area
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Indication
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Products under Development by Companies
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Companies Involved in Therapeutics Development
Chrysalis Pharma SAS
Griffin Discoveries BV
Johnson & Johnson
OSE Pharma SA
Palau Pharma, S.A.
Sensorion S.A.
Ziarco Pharma Ltd

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Drug Profiles
GD-134 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-136 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GD-48 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-28307474 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-28610244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-40279486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SENS-218 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
toreforant tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tritoqualine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UR-63325 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZPL-3893787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dormant Projects

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Discontinued Products

Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Featured News & Press Releases

Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting

Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389

Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218

Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis

Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo

Jun 18, 2014: Ziarco Secures £1.7M Grant from UK's Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis

Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Chrysalis Pharma SAS, H1 2016
Pipeline by Griffin Discoveries BV, H1 2016
Pipeline by Johnson & Johnson, H1 2016
Pipeline by OSE Pharma SA, H1 2016
Pipeline by Palau Pharma, S.A., H1 2016
Pipeline by Sensorion S.A., H1 2016
Pipeline by Ziarco Pharma Ltd, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3746933/](http://www.researchandmarkets.com/reports/3746933/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3746933/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>☐ USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>☐ USD 7000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>☐ USD 10500</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  ☐  Mrs  ☐  Dr  ☐  Miss  ☐  Ms  ☐  Prof  ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World